Organic compounds -- part of the class 532-570 series – Organic compounds – Nitrogen attached directly or indirectly to the purine ring...
Reexamination Certificate
2011-08-02
2011-08-02
Thomas, Timothy (Department: 1628)
Organic compounds -- part of the class 532-570 series
Organic compounds
Nitrogen attached directly or indirectly to the purine ring...
C514S249000, C544S238000, C544S350000
Reexamination Certificate
active
07989622
ABSTRACT:
The present invention comprises small molecule inhibitors of phosphatidylinositol 3-kinase (PI3K), which is associated with a number of malignancies such as ovarian cancer, cervical cancer, breast cancer, colon cancer, rectal cancer, and glioblastomas, among others. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting these diseases.
REFERENCES:
patent: 2006/0004010 (2006-01-01), Habashita et al.
patent: 0156880 (1973-11-01), None
patent: 1243583 (2002-09-01), None
patent: 1661889 (2006-05-01), None
patent: 2005-126549 (2005-05-01), None
patent: WO-95-26957 (1995-10-01), None
patent: WO-2004-000828 (2003-12-01), None
patent: WO-2004-007472 (2004-01-01), None
patent: WO-2005-014533 (2005-02-01), None
patent: WO-2005-021513 (2005-03-01), None
patent: WO-2005-023771 (2005-03-01), None
patent: WO 2007/023186 (2007-01-01), None
patent: WO-2007-023186 (2007-03-01), None
Budesinsky Z, et al, “Sulfanilamidoquinoxalines,” Collection of Czechoslovak Chemical Communications, 1972, pp. 887-895, vol. 37, Institute of Organic and Biochemistry, Prague, CZ.
Loriga M, et al, “Quinoxaline Chemistry. Part 4,” Il Farmaco, 1995, pp. 289-301, vol. 50, Societa Chimica Italiana, Pavia, IT.
Litvinenko S.V., et al, “Synthesis, Structure, and Chemical Properties of Some N-(3-Chloro-2-quinoxalyl)arylsulfonamides,” Chemistry of Heterocyclic Compounds, 1994, pp. 340-344, vol. 30(3), Plenum Publishing Corporation, New York, US.
Dandegaonker and Mesta, “Quinoxaline Sulfonamides,” Journal of Medicinal Chemistry, 1965, pp. 884-886, vol. 8(6), American Chemical Society, US.
Published Catalog Compounds, Database Registry, Chemical Abstracts Service, STN North America, Columbus, Ohio, www.cas.org/stn.html, Jan. 22, 2009 pp. 1-109.
CAS Registry Nos. 840497-84-9, 714932-70-4, and 573932-22-6, Database Registry, publication date Jan. 18, 2005, Chemical Abstracts Service, STN North America, Columbus, Ohio, www.cas.org/stn.html.
CAS Registry Nos. 325765-56-8 and 325765-07-9, Database Registry, date entered STN is Mar. 5, 2001 Chemical Abstracts Service, STN North America, Columbus, Ohio, www.cas.org/stn.html.
CAS Registry Nos. 560996-02-3 and 560995-76-8; Database Registry, date entered STN is Aug. 5, 2003 Chemical Abstracts Service, STN North America, Columbus, Ohio, www.cas.org/stn.html.
CAS Registry Nos. 565199-13-5, Database Registry, date entered STN is Aug. 12, 2003 Chemical Abstracts Service, STN North America, Columbus, Ohio, www.cas.org/stn.html.
CAS Registry Nos. 568570-58-1, Database Registry, date entered STN is Aug. 18, 2003. Chemical Abstracts Service, STN North America, Columbus, Ohio, www.cas.org/stn.html.
Bajjalieh William
Bannen Lynne Canne
Brown S. David
Kearney Patrick
Mac Morrison B.
Berven Heidi M.
Exelixis Inc.
Heyer Dennis
Honigman Miller Schwartz & Cohn
O'Brien Jonathan P.
LandOfFree
Phosphatidylinositol 3-kinase inhibitors and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Phosphatidylinositol 3-kinase inhibitors and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphatidylinositol 3-kinase inhibitors and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2668419